8-K: CytomX Therapeutics Announces 2024 Financial Results and Business Update; Prioritizes Lead Program CX-2051

CytomX Therapeutics reports 2024 financial results, highlighting progress with CX-2051 and CX-801, and extends cash runway into Q2 2026 through cost reductions.

Summary

• CytomX Therapeutics announced its 2024 financial results and provided a business update on March 6, 2025.
• The company is prioritizing the clinical development of CX-2051 in advanced colorectal cancer (CRC).
• CX-2051 is a masked EpCAM-targeting ADC with a topoisomerase-1 payload.
• Initial Phase 1a clinical data for CX-2051 in advanced CRC is expected in the first half of 2025.
• Phase 1a translational data for CX-801 in advanced melanoma is expected in the second half of 2025.
• CytomX has extended its cash runway into the second quarter of 2026 through cost reductions.
• In January 2025, CytomX reduced its organizational headcount by approximately 40 percent.
• CytomX ended 2024 with $100.6 million in cash, cash equivalents, and investments, compared to $174.5 million at the end of 2023.
• Total revenue for 2024 was $138.1 million, compared to $101.2 million in 2023.
• Total operating expense in 2024 was $113.1 million, compared to $107.7 million in 2023.
• Research and development expenses increased to $83.4 million in 2024 from $77.7 million in 2023.
• A $5 million milestone payment to AbbVie for dosing the first patient in the CX-2051 Phase 1 study was a primary driver of increased research and development spend.
• General and administrative expenses were essentially flat at $29.7 million for the year ended December 31, 2024.
• Astellas advanced the second program to GLP toxicology studies, triggering a $5 million milestone payment to CytomX in February 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The company is making progress with its lead program and has extended its cash runway. However, there was a headcount reduction and a decrease in cash reserves.

Positives

• Revenue increased to $138.1 million in 2024 from $101.2 million in 2023, driven by research collaborations.
• Cash runway extended into Q2 2026 due to cost reductions and focused clinical development.
• CX-2051 Phase 1 study has demonstrated a favorable tolerability profile.
• Astellas milestone achieved, resulting in a $5 million payment to CytomX.
• CX-801 Phase 1 study is currently in the fourth monotherapy dose escalation cohort where the dose of CX-801 exceeds the approved dose of the unmasked peginterferon alfa-2b (SYLATRON).

Negatives

• Cash, cash equivalents and investments decreased from $174.5 million at the end of 2023 to $100.6 million at the end of 2024.
• A 40% reduction in organizational headcount was announced in January 2025.
• CytomX and Amgen have jointly decided to not further develop CX-904.

Risks

• The forward-looking statements are subject to risks and uncertainties, including the unproven nature of the PROBODY therapeutic technology.
• There are uncertainties around the company's ability to raise sufficient funds to carry out its planned research and development.
• Clinical trial product candidates are in the initial stages of clinical development, and the process could be long and subject to significant risks and uncertainties.
• The company depends on the success of CX-2051 and CX-801.
• CytomX relies on third parties for the manufacture of its product candidates.

Future Outlook

CytomX expects to present initial Phase 1a data for CX-2051 in CRC in the first half of 2025 and Phase 1a translational data for CX-801 in advanced melanoma in the second half of 2025; the company's cash runway is expected to extend into Q2 2026.

Management Comments

• Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX, stated that CX-2051 is specifically designed to address profound unmet need in CRC.
• Dr. McCarthy said that they are encouraged by their progress to date in the first in human evaluation of CX-2051, having successfully escalated to doses predicted to be in the biologically active range.
• Dr. McCarthy believes CX-2051 is behaving as designed, and they look forward to sharing preliminary clinical data and future plans for CX-2051 in the coming months.

Industry Context

CytomX is focused on developing conditionally activated biologics for cancer treatment, a growing area of interest in the biopharmaceutical industry. The company's PROBODY platform aims to improve the safety and efficacy of cancer therapies by targeting the tumor microenvironment. The collaborations with major players like Bristol Myers Squibb, Amgen, Astellas, Regeneron, and Moderna highlight the industry's interest in CytomX's technology.

Comparison to Industry Standards

• The objective response rates in the low-single digit percentages and approximately two to four months of progression free survival in late-line CRC, as mentioned in the document, are consistent with the challenges faced in treating this patient population.
• The company's focus on EpCAM as a target is notable, as it has been historically difficult to drug due to expression on normal tissues; CytomX's PROBODY platform aims to overcome this limitation.
• Other companies are also developing ADCs for solid tumors, such as Daiichi Sankyo and Seagen, but CytomX's approach with conditionally activated biologics offers a unique angle.

Stakeholder Impact

• Shareholders: The prioritization of CX-2051 and extension of cash runway could be viewed positively, but the headcount reduction may raise concerns.
• Employees: The 40% headcount reduction will have a significant impact on affected employees.
• Patients: Progress with CX-2051 and CX-801 could potentially lead to new treatment options for cancer patients.
• Collaborators: Continued research collaborations with major pharmaceutical companies demonstrate ongoing partnerships and potential for future success.

Next Steps

• Presentation of initial Phase 1a data for CX-2051 in CRC in the first half of 2025.
• Presentation of initial Phase 1a translational data for CX-801 in advanced melanoma in the second half of 2025.
• Initiating combination therapy with CX-801 and KEYTRUDA in 2025.

Key Dates